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fumarate (TDF) and tenofovir alafenamide (TAF) are preferred treatment options for
patients with chronic hepatitis B infection (CHB). However, resistance to ETV has
been reported, especially with prior exposure to other NAs, and long-term TDF treatment has been associated with decline in renal function and loss of bone mineral
density in some patients. Consequently, TAF may be preferable to ETV, TDF or other
NAs in specific circumstances such as in patients with risk of bone or renal complications, elderly patients or those with previous NA experience.
Aim: To provide a summary of the available efficacy and safety data following switch
to TAF from other NAs in patients with CHB in clinical studies and real-world settings.
Methods: Literature searches were performed on PubMed and abstracts from three
major international liver congresses between 2019 and 2021. Studies that included
efficacy and/or safety data for patients with CHB switching from any NA to TAF were
selected.
Results: Thirty-
six papers and abstracts were included in this narrative review.
Switching from TDF to TAF maintained or improved virological and biochemical responses with improved bone and renal safety. Switching from ETV or other NAs to
TAF maintained or improved virological and biochemical responses and varying results for bone and renal safety.
Conclusions: Switching to TAF appears to maintain or improve virological, biochemical and bone-and renal-related safety outcomes. These data support the concept of
switching to TAF in some patients with CHB based on their individual circumstances.
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1 | I NTRO D U C TI O N

Following widespread regulatory approval from 2016 onward,
TAF has become a preferred CHB treatment, alongside TDF and ETV,

Hepatitis B virus (HBV) is a major global health problem.1 Despite the

in updated clinical guidelines.5,6,12,13,35 Current guidelines recom-

availability of an effective vaccine, the World Health Organization

mend TAF or ETV instead of TDF in specific circumstances, including

estimated that in 2015, 257 million people had chronic HBV infection

in patients with risk of bone or renal complications, elderly patients

(CHB). HBV infection was responsible for approximately 887 000

and in patients with previous NA treatment. TAF may be prefera-

deaths primarily due to liver cirrhosis and hepatocellular carcinoma

ble to ETV in treatment-
experienced patients (Table 1).3,5,6,12,13

1

(HCC). Patients with CHB live on average 14 years less than the

Despite these recommendations, many patients remain on non-TAF

general population due to multiple causes. 2 The main goal of CHB

therapies.

treatment is to prevent disease progression and HCC development,

The aim of this narrative review was to summarise the available

thereby improving survival and quality of life.3-6 Hepatitis B surface

virological, biochemical and renal-and bone-related safety data fol-

antigen (HBsAg) loss or seroconversion is the optimal treatment

lowing switch to TAF from other NAs in clinical studies and real-

endpoint. However, HBsAg loss rarely occurs with current therapies,

world settings.

so antiviral treatment is generally life-long. Safety is paramount for
long-term treatment approaches. Recent studies have shown that
the mean age of patients with CHB has increased significantly over

1.1 | Search strategy and selection criteria

the past two decades. This increasing proportion of CHB patients
with advanced age carries with it the associated increases in comor-

PubMed searches were performed using search terms “tenofovir

bidities, including chronic kidney disease (CKD), osteoporosis, bone

alafenamide”, “hepatitis B OR HBV OR CHB” and “switch OR switch-

fractures and cardiovascular disease (CVD).7-11 The presence of co-

ing”. Abstracts from three major international liver congresses (The

morbidities in an ageing CHB patient population means that long-

International Liver Congress, The Liver Meeting and The Conference

term safety of antiviral therapies must be optimised.

of the Asian Pacific Association for the Study of the Liver) in 2019,

Current preferred antiviral treatments are nucleos(t)ide ana-

2020 and 2021 were searched using the term ‘alafenamide’. Studies

logues (NAs) such as entecavir (ETV), tenofovir disoproxil fuma-

that included efficacy and/or safety data for patients with CHB

rate (TDF) and tenofovir alafenamide (TAF). 3-6 ,12,13 ETV, TDF and

switching from any NA to TAF were selected. Data from the most

TAF are potent NAs with a high barrier to resistance that have

recent abstract or any subsequently published papers were in-

demonstrated high long-term antiviral efficacy and a favourable

cluded. Thirty-six papers and abstracts were included in this narra-

safety profile. 3 However, ETV has a high barrier to resistance only

tive review.

in NA treatment-naïve CHB patients and not in patients previously
exposed to NAs with a low barrier to resistance. 3,14-16 TDF resistance has been reported but is rare,17,18 and no resistance to TAF

1.2 | Switching from TDF to TAF

has been reported. 3 Patients who develop NA resistance should
switch NA treatment according to the pattern of prior NA treatments.

3-5

Approximately half of the publications on TAF switching come from

In some patients treated with TDF, declines in renal

studies in CHB patients previously treated with TDF, including the

function19-23 and reductions in bone mineral density (BMD) have

only Phase 3, randomised, double-blind, non-inferiority study and

been reported.19,24-27 These side effects are uncommon but could

several sub-analyses of this study and its extension. Results have

be problematic for long-term TDF treatment in an ageing CHB

shown that switching from TDF to TAF maintained or improved vi-

population with comorbidities.

rological and biochemical response with improved renal and bone

TAF is the oral phosphonamidate prodrug of tenofovir and has
greater stability in plasma compared with TDF.

28

safety (Table 2, Figures 1 and 2).36-52

TAF provides

targeted delivery of tenofovir directly to the liver. 29,30 Circulating
plasma concentrations of tenofovir in patients with CHB are ap-

1.2.1 | Virological and biochemical response

proximately 90% lower with TAF compared with TDF at approved
doses.31 In Phase 3 trials of patients with CHB, TAF was non-inferior

In studies of CHB patients with undetectable HBV DNA at base-

to TDF in terms of antiviral efficacy, with no resistance to treatment

line, switching from TDF to TAF maintained virological and bio-

19,32,33

TAF treatment was associated with

chemical responses (Table 2). 36,43,47 In a double-b lind Phase 3

significantly smaller reductions in BMD and improvements in creati-

study in 488 patients with CHB who had received TDF for at least

nine clearance as well as markers of renal tubular function compared

48 weeks, patients were randomised to continue TDF treatment

with TDF at Weeks 48 and 96.19,32,33 In a pooled analysis of patients

or switch to TAF. 36 At Week 48, over 99% of patients in both

aged at least 65 years treated in Phase 2 and 3 trials, the efficacy and

treatment groups had HBV DNA below 20 IU/ml. More patients

safety of TAF was generally similar to that reported in younger pa-

achieved alanine aminotransferase (ALT) normalisation with TAF

tients, with small improvements in renal and bone parameters noted

compared with TDF. Further analyses were performed at Week

in older patients switched from TDF to TAF.34

96 after all patients had received open-label TAF for an additional

reported up to 96 weeks.

|
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TA B L E 1 Summary of indications for
selecting ETV or TAF over TDF

Guideline

Recommendations

EASL 20173

• Age > 60 years
• Bone disease
• Chronic steroid use or use of other medications that reduce BMD
• History of fragility fracture
• Osteoporosis
• Renal alterationa
• eGFR <60 ml/min/1.73 m2
• Albuminuria >30 mg/24 h or moderate dipstick proteinuria
• Low phosphate (<2.5 mg/dl)
• Haemodialysis
• TAF should be preferred to ETV in patients with previous NA exposure

AASLD
20185

• Consider TAFb or ETV in patients with or at risk of renal dysfunction or
bone disease
• In cases of suspected TDF-associated renal dysfunction and/or bone
disease, TDF should be discontinued and substituted with TAF or ETV, with
consideration for previous known drug resistance

KASL 20196

• Bone disease
• Chronic steroid use
• Use of medication that worsens BMD
• Osteoporosis or osteopenia
• Renal alterationb
• eGFR <60 ml/min/1.73 m2
• Dipstick proteinuria or urine albumin/creatinine >30 mg/g
• Low serum phosphate (<2.5 mg/dl)
• TAF should be preferred to ETV in patients with previous NA exposure
• In treatment-adherent patients with partial virological response, switch
from one NA to another NA option with no cross resistance
• For ETV-resistant CHB, switch to tenofovir monotherapy or add tenofovir

CSH/CMA/
CSID
201912

• In patients with CKD, renal failure or receiving renal replacement therapy,
ETV or TAF is recommended
• Patients treated with TDF should switch to ETV or TAF if they suffer from
renal or bone disease, or are at high risk

JSH 201913

• TAF and ETV are preferred first-line drugs for patients with renal
impairment, hypophosphataemia or osteopenia/osteoporosis at treatment
initiation
• Switching from TDF to TAF is recommended for patients with renal
impairment, hypophosphataemia or osteopenia/osteoporosis
• Switching from combination therapy with ETV + TDF to ETV + TAF is
recommended for patients with renal impairment, hypophosphataemia or
osteopenia/osteoporosis

3

AASLD, American Association for the Study of Liver Diseases; BMD, bone mineral density;
CHB, chronic hepatitis B virus infection; CKD, chronic kidney disease; CMA, Chinese Medical
Association; CrCl, creatinine clearance; CSH, Chinese Society of Hepatology; CSID, Chinese
Society of Infectious Disease; EASL, European Association for the Study of the Liver; eGFR,
estimated glomerular filtration rate; ETV, entecavir; JSH, Japan Society of Hepatology; KASL,
Korean Association for the Study of the Liver; NA, nucleos(t)ide analogue; TAF, tenofovir
alafenamide; TDF, tenofovir disoproxil fumarate.
a

ETV dose needs to be adjusted if eGFR <50 ml/min; no TAF dose adjustment is required in adults
or adolescents (aged ≥12 years or ≥ 35 kg body weight) with estimated CrCl ≥15 ml/min or in
patients with CrCl <15 ml/min who are receiving haemodialysis;

b

TAF is not recommended in patients with CrCl <15 ml/min or those on dialysis.

48 weeks. The proportion of patients with virological suppression

In studies where some patients had detectable HBV

was maintained, and rates of ALT normalisation increased in both

DNA

groups. These results were supported by results from two pro-

(Table 2).42,44-4 6,48,50-52 Results from an international retrospec-

at

baseline,

similar

efficacy

results

were

reported

spective single-centre studies of patients with at least 12 months

tive study of 834 patients who switched to TAF after at least

of TDF treatment and HBV DNA below 20 IU/ml, in which virologi-

12 months of TDF showed that virological and biochemical pa-

cal and biochemical responses were maintained to Week 24 after

rameters were stable over 24 months. 51 Maintenance of virologi-

switching.43,47

cal response 24 weeks after switching from TDF to TAF was also

TAF: n = 243 TDF: n = 245
Mean age: 51 y
Male: 71%
HBV DNA <20 IU/ml and
HBV DNA < LLOQ for
≥12 weeks at screening
HBeAg +ve: 32%
Median ALT level at BL, U/L:
23 (TAF), 24 (TDF)

Phase 3, randomised,
double-blind, Week
48 analysis
GS-US-320-4 018

Phase 3, randomised,
double-blind, Week
48 analysis
GS-US-320-4 018

Phase 3, randomised,
double-blind, Week
48 Asian subset
analysis
GS-US-320-4 018

Lampertico
2020a36

Buti 201937

Ahn 202038
TAF: n = 143 TDF: n = 145
Pts of Asian ethnicity with
≥1 risk factor for TDF
toxicityb
Mean age: 53 y (TAF), 54 y
(TDF)
Male: 64%
HBV DNA <20 IU/ml and
HBV DNA < LLOQ for
≥12 weeks at screening
HBeAg +ve: 35%
Median ALT level at BL, U/L:
23

TAF: n = 180 TDF: n = 178
Pts with ≥1 risk factor for
TDF toxicityb
Mean age: 53 y (TAF), 54 y
(TDF)
Male: 66%
HBV DNA <20 IU/ml and
HBV DNA < LLOQ for
≥12 weeks at screening
HBeAg +ve: 29%
Median ALT level at BL, U/L:
23

Pt population

Type of study

Studies of patients switching from TDF to TAF

Study

TA B L E 2

ALT

TDF: 100%
Pts with HBV DNA
Other: NR
<20 IU/ml at
See Lampertico
Week 48
2020a for full
• TAF: 97%
study population • TDF: 97%

Pts with normal ALT
(AASLD)a at Week
48
• TAF: 76%
• TDF: 73%

Pts with normal ALT
(AASLD)a at Week
48
• TAF: 79%
• TDF: 76%

HBV DNA ≥20 IU/
ALT normalisation
ml in 1 pt (<1%) at
rate at Week 48
Week 48 in each
(AASLD)a
group (difference
• TAF: 50%
in proportion
• TDF: 26%;
0.0%, 95% CI, −1.9
P = 0.014
to 2.0)

HBV DNA

TDF: 100%Other:
Pts with HBV DNA
NR
<20 IU/ml at
See Lampertico
Week 48
2020a for full
• TAF: 97%
study population • TDF: 97%; P = 0.96

TDF: 100%
LAM: 39%
ADV: 38%
ETV: 20%
TBV: 10%
Other: 5%

Prior NAs

Effectiveness

Mean % change in spine
BMD at Week 48
• TAF: +1.92
• TDF: −0.52; P < 0.0001
Mean % change in hip
BMD at Week 48
• TAF: +0.64
• TDF: −0.73; P < 0.0001

Mean % change in spine
BMD at Week 48
• TAF: +1.81
• TDF: −0.33; P < 0.001
Mean % change in hip
BMD at Week 48
• TAF: +0.67
• TDF: −0.53; P < 0.001

Mean % change in spine
BMD at Week 48
• TAF: +1.74
• TDF: −0.11; P < 0.0001
Mean % change in hip
BMD at Week 48
• TAF: +0.66
• TDF: −0.51;
P < 0.0001Improved
markers of bone
turnover (CTX, P1NP)
TAF vs TDF

Bone effects

Safety

Median change in eGFRCG
at Week 48, ml/min
• TAF: +2.61
• TDF: −2.67; P < 0.0001

Median change in eGFRCG
at Week 48, ml/min
• TAF: +1.86
• TDF: −2.70; P < 0.001

Median change in eGFRCG
at Week 48, ml/min
• TAF: +0.94
• TDF: −2.74; P < 0.0001
Pts with Grade ≥ 1
proteinuria at Week 48
• TAF: 14%
• TDF: 22%;
P = 0.013Improved
markers of tubular
function (urinary RPB/
Cr and β2M/Cr ratios)
TAF vs TDF

Renal effects

4
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TAF-TAF: n = 243 TDF-TAF:
n = 245
HBeAg +ve: 32%
See Lampertico 2020a for
study details

Phase 3, open-label
extension, Week 96
analysis
GS-US-320-4 018

Phase 3, open-label
extension, Week
96 Asian subset
analysis
GS-US-320-4 018

Retrospective,
multicentre, real
world

Randomised,
multicentre

Lampertico
2020b39d

Ahn 202140

Ãtelen 2020 41

Byun 202142
TAF: n = 87 TDF: n = 87
Mean age: 55 y
Male: 81%
Pts with detectable HBV
DNA (>15 IU/ml) at BL:
14.9%
HBeAg +ve: 62%
Median ALT level at BL, IU/L,
25

N = 480
Mean age: 47 y
Male: NR
HBV DNA level at BL: NR
HBeAg +ve: 20%
ALT level at BL: NR

TAF: n = 189 TDF: n = 198
Pts of Asian ethnicity
Median age: 52 y (TAF), 51
y (TDF)
Male: 70%
HBV DNA <20 IU/ml and
HBV DNA < LLOQ for
≥12 weeks at screening
HBeAg +ve: 35%
Median ALT level at BL, U/L:
24

Pt population

Type of study

Study

TA B L E 2 (Continued)

Pts with HBV DNA
<20 IU/ml at
Week 96
• TAF-TAF: 95%
• TDF-TAF: 94%

HBV DNA

NR

LAM/ETV/ADV:
Pts with HBV DNA
71%
<60 IU/ml
LAM/ADV: 12%
• BL: TAF 96.6% vs
LAM/ETV: 10%
TDF 92.0%
ETV/ADV: 4%
• Week 48: TAF
ETV: 3%
98.9% vs TDF
ADV: 1%
97.7%; P > 0.99
Genotypic
resistance to
ADV and/or ETV

TDF: 86%
Other: NR

TDF: 100%
Pts with HBV DNA
Other: NR
<20 IU/ml at
See Lampertico
Week 96
2020a for full
• TAF-TAF: 95%
study population • TDF-TAF: 94%

TDF: 100%
LAM: 39%
ADV: 38%
ETV: 20%
TBV: 10%
Other: 5%

Prior NAs

Effectiveness

Median (IQR) ALT
change at Week
48, IU/L
• TAF: −3 (−8, 3)
• TDF: −2 (−5, 6);
P = 0.02
Pts with normal ALT
(central)a at Week
48
• TAF: 88.5%
• TDF: 81.2%;
P = 0.26

NR

Pts with normal ALT
(central)a at Week
96
• TAF-TAF: 88%
• TDF-TAF: 91%
Pts with normal ALT
(AASLD)a at Week
96
• TAF-TAF: 79%
• TDF-TAF: 86%

ALT normalisation
rate at Week 96
(AASLD)a
• TAF-TAF: 56%
• TDF-TAF: 74%;
P = 0.051

ALT

Mean % change in spine
BMD at Week 48
• TAF: +1.8
• TDF: +0.2; P = 0.02
Mean % change in hip
BMD at Week 48
• TAF: −0.2
• TDF: −0.3; P = 0.90

Significant improvement in
spine and hip BMD at
month 6 (P = 0.05)

|
(Continues)

Median % change in
eGFRCG at Week 48
• TAF: +7.3
• TDF: +1.9; P = 0.047
Median change in sCr at
Week 48, mg/dl
• TAF: −0.1
• TDF: 0.0; P = 0.09

Significant improvement in
eGFR and phosphorus
levels at Month 6
(P = 0.05)

Median change in eGFRCG
at Week 96, ml/min
• TAF-TAF: +1.26
• TDF-TAF: +0.01

Median change in eGFRCG
from Week 0 to 96,
ml/min
• TAF-TAF: +0.51
• TDF-TAF: −0.39;
P = 0.871

Mean % change in spine
BMD at Week 96
• TAF-TAF: +2.33
• TDF-TAF: +1.73;
P = 0.097
Mean % change in hip
BMD at Week 96
• TAF-TAF: +1.16
• TDF-TAF: +0.18;
P < 0.001Similar
improvements in CTX
and P1NP between
groups
Median % change in spine
BMD at Week 96
• TAF-TAF: +2.47
• TDF-TAF: +1.55
Median % change in hip
BMD at Week 96
• TAF-TAF: +1.23
• TDF-TAF: +0.12

Renal effects

Bone effects

Safety

LIM et al.
5
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Kaneko
201946

N = 176
Mean age: 52 y
Male: 73%
Pts with detectable HBV
DNA at BL: 36%
HBeAg +ve: 20%
Median ALT level at BL, U/L:
27
Pts with CKD Stage 1: 29%
Stage 2: 36% Stage 3a:
20% Stage 3b+: 15%

Pt population

Prospective, single
centre

N = 36
Median age: 55 y
Male: 75%
Median HBV DNA at BL:
0 IU/ml
HBeAg +ve: 25%
Median ALT level at BL, U/L:
24

N = 60
Mean age: 55 y
Male: 28%
Mean HBV DNA at BL:
450 IU/ml
HBeAg +ve: 28%
Mean ALT at BL, IU/L: 25

Prospective, single arm, N = 75
open label
Median age: 58 y
Male: 65%
Pts with HBV DNA <20 IU/
ml at BL: 100%
HBeAg +ve: NR
Median ALT at BL, U/L: 23

Real-world, multicentre
(CANHEPB
network)

Type of study

Huynh 2020 45 Retrospective, single
centre

Fong 201943

Farag 2021

Study

TA B L E 2 (Continued)

TDF: 100%
Other: NR

TDF: 100%
Other: NR

TDF: 100%
ADV: 0%
Other: NR

TDF: 73%
ETV: 3%
LAM: 2%
Other: 4%
Naïve: 19%

Prior NAs

No elevation in HBV
DNA levels at
Week 24

NR

Pts with HBV
DNA < 20 IU/ml
at Week 24
• 97%c

Pts with HBV DNA
<20 IU/ml (prior
TDF cohort)
• BL: 72%
• Week 52: 84%

HBV DNA

Effectiveness

NR

Pts with normal ALT
(AASLD)a
• BL: 78%
• Week 96: 86.5%

No significant change
from BL

NR

ALT

NR

NR

Mean % change in BMD at
Week 24
• Spine: +3.1; P < 0.01
• Hip: +12.8;
P < 0.01Significant
improvements in hip
and lumbar total T-
scores (P < 0.01)

NR

Bone effects

Safety

Mean change in eGFR, ml/
min/1.73 m2
• Week 4: +3.93;
P = 0.008
• Week 12: +3.88;
P = 0.039
• Week 24: +2.89;
P = 0.020Significant
decline in β2M/Cr ratio
at Weeks 12 and 24
post switch (P = 0.002
and P = 0.027,
respectively)

NR

No significant change in
eGFRCG from BL to
Week 24
Significant improvements
in urinary RPB/Cr and
β2M/Cr ratios at weeks
12 and 24 (P < 0.01)

eGFR change, ml/min/
month
• Pre-TAF: −0.18;
P = 0.008
• TAF: 0.00;
P = 1.0Kidney function
deterioration was
halted after switching
to TAF

Renal effects

6

|
LIM et al.

47

N = 26
No details provided

Single centre

Multicentre (TRIO
cohort)

Notsumata
2020 49

Reddy 201950
N = 270
Mean age: 53 y
Male: 59%
Pts with HBV DNA
≤2000 IU/ml at BL: 97%
HBeAg +ve: NR
Mean ALT level at BL, U/L: 28

N = 146
Median age: 69 y
Male: 71%
Pts with undetectable HBV
DNA at BL: 94%
HBeAg +ve: 6%
Median ALT level at BL, IU/L:
21

N = 61
Median age: 57 y
Male: 59%
Pts with HBV DNA <20 IU/
ml at BL: 100%
HBeAg +ve: NR
Median ALT level at BL, U/L:
24

Pt population

Prospective,
observational

Prospective, single
centre

Type of study

Loglio 2020 48

Lee 2021

Study

TA B L E 2 (Continued)

TDF: 82%
ETV: 8%
ADV: 1%
TBV: <1%

NR

TDF: 100%
LAM or ETV: 100%
ADV: 65%
Other: NR

TDF: 100%
ADV: 0%
Other: NR

Prior NAs

Pts with HBV DNA
≤2000 IU/ml at
Week 48
• 100%; P = 0.011

NR

Virological control
maintained over
6 months

NR

HBV DNA

Effectiveness

Mean ALT level, U/L
• BL: 28
• Week 48: 24;
P = 0.013
Pts with normal ALT
(AASLD)a
• BL: 78%
• Week 48: 83%;
P = 0.053

NR

Median ALT level at,
IU/L
• Month 2: 21
• Month 6: 2

Pts with normal ALT
(AASLD)a
• BL: 74%
• Week 24: 77%
• Week 72: 80%

ALT

NR

FGF23, pg/ml
• BL: 29.6
• Week 4: 38.6; P = 0.001
• Week 12: 46.7;
P = 0.012

NR

Mean % change in BMD at
Week 24:
• Spine: +3.3; P < 0.01
• Hip: +13.5; P < 0.01

Bone effects

Safety

(Continues)

Pts with eGFR <60 ml/min
• BL: 7%
• Week 48: 9%; P = 0.366

Urinary L-FABP, μg/gCr
• BL: 20.53
• Week 4: 8.9; P = 0.022
• Week 12: 3.01;
P = 0.008

eGFRCG level, ml/min
• BL: 68
• Month 6: 67
eGFRMDRD level, ml/min
• BL: 66
• Month 6: 66
Urinary β2M/Cr ratio,
mg/g
• BL: 658
• Month 6: 315
UP/Cr ratio, mg/g
• BL: 82
• Month 6: 52

Mean % change in eGFRCG:
• Week 24: −0.6
• Week 72: −5.2; P < 0.01

Renal effects

LIM et al.
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Retrospective,
multicentre

Retrospective,
multicentre

Type of study

N = 121
Mean age: 55 y
Male: 72%
Pts with HBV DNA <20 IU/
ml at BL: 89.3%
HBeAg +ve: 21%
Mean ALT level at BL, U/L: 36

N = 834
Mean age: 55 y
Male: 57%
Pts with HBV DNA <20 IU/
ml at BL: 88.2%
HBeAg +ve: 31%
Mean ALT level at BL, U/L: 29
eGFR ≥90 ml/min: n = 463
eGFR 60–89 ml/min: n = 267
eGFR <60 ml/min: n = 85

Pt population

TDF: 75%
ETV: 5%
LAM: 3%
Other: 18%

TDF: 100%
ETV: 45%
ADV: 33%
LAM: 14%
Other: 7%

Prior NAs

Pts with HBV DNA
<20 IU/ml at
Month 12:
• 96.2%; P = 0.016

Pts with HBV DNA
<20 IU/ml at
Week 96
• 94.9%; P < 0.001

HBV DNA

Effectiveness

Pts with normal ALT
(AASLD)a
• BL: 58.7%
• Month 12: 70.2%;
P = 0.029

Pts with normal ALT
(AASLD)a
• BL: 69.6%
• Week 96: 77.8%;
P = 0.003

ALT

NR

NR

Bone effects

Safety

Mean % change in eGFR at
Month 12
• Total cohort: −1.0%;
P = 0.278
• CKD cohort: +2.8%;
P = 0.02715.1% of pts
with CKD stage 2 and
33.3% of pts with CKD
stage 3 had one CKD
stage improvement

Pts with eGFR ≥90 ml/min
at BL: 11.2% changed
to eGFR 60–89 ml/min
at Week 96
Pts with eGFR 60–89 ml/
min at BL: 4.9%
changed to eGFR
<60 ml/min at Week
96; 20.6% improved to
eGFR ≥90 ml/min at
Week 96
Pts with eGFR <60 ml/min
at BL: 1.2% improved
to eGFR ≥90 ml/min
at Week 96; 35.3%
improved to eGFR 60–
89 ml/min at Week 96

Renal effects

In the extension study, patients switched to TAF at baseline continued treatment with TAF (TAF-TAF) and patients treated with TDF during the initial randomised study were switched to TAF at Week 48
(TDF-TAF).

d

Two patients had HBV DNA >21 IU/ml; both patients were non-compliant as measured by pill count.

c

According to EASL and AASLD guidelines.

According to EASL and AASLD guidelines.

b

a

Abbreviations: AASLD, American Association for the Study of Liver Diseases; ADV, adefovir; ALT, alanine aminotransferase; β2M/Cr, β2 microglobulin to creatinine; BL, baseline; BMD, bone mineral
density; CI, confidence interval; CKD, chronic kidney disease; Cr, creatinine; CTX, C-t ype collagen sequence; EASL, European Association for the Study of the Liver; eGFR, estimated glomerular filtration
rate; eGFRCG , estimated glomerular filtration rate Cockcroft-Gault formula; eGRFMDRD, estimated glomerular filtration rate Modification of Diet in Renal Disease; ETV, entecavir; FGF, fibroblast growth
factor; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; IQR, interquartile range; LAM, lamivudine; L-FABP, liver-t ype fatty acid-binding protein; LLOQ, lower limit of quantification; NA, nucleos(t)ide
analogue; NR, not reported; P1NP, procollagen type 1 N-terminal propeptide; pt, patient; RBP/Cr, retinol binding protein to creatinine; sCr, serum creatinine; TAF, tenofovir alafenamide; TBV, telbivudine;
TDF, tenofovir disoproxil fumarate; UP/Cr, urine protein to creatinine; y, years.

Yeh 201952

Toyoda 2021

Study

TA B L E 2 (Continued)
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F I G U R E 1 Schematic showing the proportion of patients with HBV DNA < 20 IU/ml in studies in patients with CHB switching from
TDF or ETV to TAF. The upper panels show results from TDF to TAF switching studies and the lower panels show results from ETV to TAF
switching studies. Results from comparative studies are shown in the panels on the left and results from single-arm studies are shown in the
panels on the right. Only those studies reporting the proportion of patients with HBV DNA <20 IU/ml are included. No direct comparisons
between study results can be made due to differences in study designs and patient populations. Primary endpoints were the proportion of
patients with HBV DNA <20 IU/ml (Lampertico 2020a,36 Lampertico 2020b,39 Yeh 2019,52 Li 2021,58 Arai 2021,54 Ogawa 202059), complete
response defined as the HBV DNA <20 IU/ml plus ALT normalisation (≤35 U/L for males and ≤ 25 U/L for females; Toyoda 2021,51 Ogawa
202160) or not specified (Fong 2019,43 Uchida 202061). ALT, alanine aminotransferase; CHB, chronic hepatitis B infection; ETV, entecavir;
HBV, hepatitis B virus; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate
reported in a prospective, single-centre study of 36 patients.46 In a

Not all TDF to TAF switching studies reported bone-related

retrospective, single-centre study of 60 patients treated with TDF

safety outcomes; however, those that did generally reported im-

and then switched to TAF for 2 years, the authors reported an in-

provements (Table 2).36,39-43,47 In a prospective, single-arm study,

crease in the proportion of patients with ALT improvements from

BMD significantly increased from baseline to Week 24 in 75 patients

baseline at Week 96.45 Improvements in virological and biochem-

switched from TDF to TAF.43 Forty percent of patients had osteo-

ical responses were also reported in a retrospective study of 121

penia at baseline, but no change in BMD in this patient population

patients switched to TAF after at least 12 months of treatment

was reported. Results from the Phase 3 TDF to TAF switching study

with another NA (75% prior TDF)52 and a study of 270 patients

showed that patients who switched to TAF had significant improve-

switched to TAF in routine clinical practice and remaining on TAF

ments in BMD at Week 48 compared with patients continuing TDF.36

for at least 48 weeks.

50

1.2.2 | Renal and bone safety

1.2.3 | Additional safety outcomes of interest
Fasting lipid analysis was performed in the Phase 3 TDF to TAF

In all studies where renal safety outcomes were reported, improve-

switching study at Week 96.39 In patients switched to TAF at base-

ments were generally observed upon switching from TDF to TAF

line, total, low-density lipoprotein (LDL) and high-density lipopro-

(Table 2).36,39-42,46,47,51 In the Phase 3 TDF to TAF switching study,

tein (HDL) cholesterol levels increased after switch. In patients who

TAF-treated patients had significantly improved renal safety parame-

switched to TAF at Week 48, corresponding increases in total, LDL

ters at Week 48 compared with TDF-treated patients.34 In other stud-

and HDL cholesterol levels after switch were observed. Levels of

ies, evaluations of estimated glomerular filtration rate (eGFR) mostly

total, LDL and HDL cholesterol were similar between treatment

showed improvements upon switching from TDF to TAF.41,46,47,51

groups at Week 96. The total to HDL cholesterol ratio remained

10
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F I G U R E 2 Schematic showing the proportion of patients with normal ALT according to the AASLD 2018 criteria in studies in patients
with CHB switching from TDF or ETV to TAF. The upper panels show results from TDF to TAF switching studies and the lower panels show
results from ETV to TAF switching studies. Results from comparative studies are shown in the panels on the left and results from single-arm
studies are shown in the panels on the right. Only those studies reporting the proportion of patients with normal ALT according to AASLD
2018 criteria are included. No direct comparisons between study results can be made due to differences in study designs and patient
populations. AASLD 2018 criteria are ≤35 U/L for males and ≤ 25 U/L for females. Primary endpoints were the proportion of patients with
HBV DNA <20 IU/ml at Week 48 (Lampertico 2020a,36 Yeh 2019,52 Li 202158), HBV DNA <60 IU/ml (Byun 202242), complete response
defined as the HBV DNA <20 IU/ml plus ALT normalisation (AASLD 2018 criteria; Toyoda 2021,51 Ogawa 202160) or not specified (Huynh
2020,45 Reddy 201950). AASLD, American Association for the Study of Liver Diseases; ALT, alanine aminotransferase; CHB, chronic hepatitis
B infection; ETV, entecavir; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate

unchanged. Median change in body weight at Week 96 increased by

study evaluated 146 patients switched from TDF to TAF according

1.4 and 1.0 kg in patients who switched from TDF to TAF at base-

to European Association for the Study of the Liver (EASL) criteria.3,48

line and at Week 48, respectively. Increased fasting lipids were also

Patients were switched because of age (80% were over 60 years old),

reported in a 5-year analysis of the TAF registrational studies upon

osteoporosis or steroid treatment (34%) or renal disease (56%). In this

53

Results from a randomised study of

population, virological and biochemical parameters were maintained

176 patients with multidrug-resistant HBV showed greater increases

over 6 months of TAF treatment. Estimated GFR remained stable

switching from TDF to TAF.

in total, LDL and HDL cholesterol levels from baseline to Week 48

over 6 months, but rapid improvements were seen in β2 microglobu-

in patients switched to TAF compared with patients continuing TDF

lin (β2M)/creatinine and urine protein/creatinine ratios. The authors

(P < 0.01 for all).42 However, the total to HDL cholesterol ratio de-

concluded that switching from TDF to TAF rapidly improves proxi-

creased slightly upon TAF switching. Body mass index (BMI) changed

mal tubular function in an elderly population with long-term expo-

significantly over the study in the TAF group vs TDF group (+0.71 kg

sure to TDF. As part of the Phase 3 TDF to TAF switching study,36 a

vs −0.37 kg; P = 0.01). BMI also significantly increased (+0.6 kg;

subgroup analysis of patients with risk factors for TDF toxicity was

P < 0.01) in 61 patients enrolled in a prospective, single-centre study

performed.37 Risk factors included age over 60 years, osteoporosis,

at Week 72 after switching from TDF to TAF.

stage 2 and above CKD, albuminuria, hypophosphataemia, obesity or

47

comorbidities associated with CKD. These risk factors are similar to
the EASL switching criteria. For patients included in this analysis, an-

1.2.4 | Special patient populations

tiviral efficacy was maintained and significant improvements in bone
and renal safety parameters were observed after TAF switching.

Several studies have evaluated switching from TDF to TAF in specific

Various guidelines support switching from TDF to TAF in pa-

patient populations (Table 2).38,42-4 4,48,51,52 A prospective, real-world

tients with CKD (Table 1). In a study of 176 patients with CKD from

N = 38
Mean age: NR
Male: NR
HBV DNA <20 IU/ml at BL, n = 24
HBV DNA 20–2000 IU/ml at BL,
n = 14
HBeAg +ve: NR
ALT level at BL: NR

ETV: 100%
N = 48 (24 switched to TAF)
Other: 0%
Mean age: 61 y (TAF), 55 y (ETV)
Male: 25% (TAF), 42% (ETV)
HBV DNA-positive for ≥6 months
prior to ETV treatment
HBV DNA <1.3 log10 IU/ml at switch
HBeAg +ve: 15%
Mean ALT level at BL, IU/L: 20 (TAF),
18 (ETV)

TAF: n = 71 ETV: n = 71
Median age: 61 y (TAF), 58 y (ETV)
Male: 63% (TAF), 59% (ETV)
HBV DNA <1.3 log10 IU/ml for
>6 months prior to switch
HBeAg +ve: 9%
Median ALT level at BL, IU/L: 20
(TAF), 19 (ETV)

Single centre

Prospective,
single centre,
comparative

Retrospective,
multicentre

Hagiwara
201956

Itokawa
202057

Prior NAs

ETV: 100%
Other: 0%

ETV: 100%
Other: NR

ETV: 100%
Other: 0%

Chen 202155

Pt population

Multicentre,
multinational,
real world

N = 425
Mean age: 61 years
Male: 60%
Pts with HBV DNA <20 IU/ml at BL:
91.9%
HBeAg +ve: NR
Mean ALT level at BL, U/L: 19
Pts with CKD Stage 1: 55.6% Stage
2: 35.7% Stages 3–5: 8.8%
8.3% of pts had HCC

Type of study

Arai 202154

Studies of patients switching from ETV to TAF

Study

TA B L E 3

NR

NR

HBV DNA suppression rate
• BL: 55.3%
• Week 24: 92.1%; P < 0.05

Pts with HBV DNA <20 Ul/ml
• Week 48: 95.6%; P = 0.03
• Week 96: 97.2%; P = 0.02

HBV DNA

Effectiveness

No significant difference
between groups

No significant difference
between groups

ALT normalisation ratea
• BL: 94.7%
• Week 24: 94.7%

No significant change in
ALT levels

ALT

NR

No significant
change
in lumbar
vertebrae or
femur bone
mineralisation
was seen over
48 weeks in
either group

NR

NR

Bone effects

Safety

(Continues)

Median change in eGFR at Week 48,
ml/min/1.73 m2
• TAF: −1.0
• ETV: −0.5; P = 0.604

No significant difference in
changes in eGFR, UA/Cr ratio
or phosphorus levels between
groups

No significant difference in eGFR

11% of CKD stage 1 pts changed to
stage 2
8% of CKD stage 2 pts changed to
stages 3–5 and 18% changed to
stage 1
19% of CKD stage 3–5 pts changed
to stage 2

Renal effects

LIM et al.
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ETV: 100%
Other: NR

ETV: 100%
Other: 0%

N = 199
Mean age: 58 y
Male: 58%
Pts with HBV DNA <20 Ul/ml at BL:
93.5%
HBeAg +ve: 16%
Mean ALT level at BL, U/L: 25

Uchida 202061 Prospective, single N = 92
centre
Median age: 62 y
Male: 52%
Pts with HBV DNA <20 IU/ml at BL:
96.7%
HBeAg +ve: 14%
Median ALT level at BL, U/L: 16

Ogawa 202160 Prospective,
multicentre
Interim analysis

N = 191
Median age: 62 y
Male: 63%
Pts with HBV DNA level at BL, IU/ml
• <20: 75.9%
• 20–2000: 19.9%
• >2000: 4.2%HBeAg +ve: 12%
Median ALT level at BL, U/L: 20
History of HCC: 9.4%

Multicentre,
retrospective,
cohort

Ogawa
202059

ETV: 100%
Other: 40%

NR

N = 38
No details provided

Prior NAs

Single centre

Pt population

Notsumata
2020 49

Type of study
ETV: 100%
Other: 0%

58

Prospective, single N = 211 (102 switched to TAF)
centre
Mean age: 48 y
Male: 81%
Persistent low level viraemia (HBV
DNA >20–<2000 IU/ml)
Mean HBV DNA at BL, log10 IU/
ml: 2.3
HBeAg +ve: 68%
Mean ALT at BL, U/L: 33

Li 2021

Study

TA B L E 3 (Continued)

Pts with HBV DNA <20 IU/ml at
Week 48
• 98.9%

Pts with HBV DNA <20 IU/ml
• Month 12: 96.8%

Pts with HBV DNA <20 IU/ml at
Week 48
• 96.9%
Pts with HBV DNA <20 IU/ml at
Week 48 by BL level
• 20–2000 (n = 34): 97.1%
• >2000 (n = 12); 75.0%

NR

Pts with HBV DNA <20 IU/ml at
Week 24
• TAF: 62.7%
• ETV: 9.3%; P < 0.001
Mean HBV decrease at Week 24,
log10 IU/ml
• TAF: 1.99
• ETV: 0.76; P = 0.002

HBV DNA

Effectiveness
Bone effects

Median ALT levels, IU/L
• BL: 16
• Week 8: 17; P = 0.002
• Week 24: 17;
P = 0.038
• Week 48: 16; P = ns

NR

NR

NR

Pts with normal ALTc
• BL: 55.5%
• Week 48: 73.8%;
P < 0.001

Pts with normal ALT
(AASLD)b
• BL: 87.9%
• Month 12: 93.0%

Mean FGF23 level,
pg/ml
• BL: 34.7
• Week 12: 42.5;
P = 0.004

NR

Pts with normal ALT
NR
(central)b at Week 24
• TAF: 47.6%
• ETV: 10.5%; P = 0.027
Pts with normal ALT
(AASLD)b at Week 24
• TAF: 48.0%
• ETV: 14.8%; P = 0.022

ALT

Safety

No significant difference in eGFR or
phosphate levels at Week 48

NR

Mean change in eGFR at Week 48,
ml/min/1.73 m2
• eGFR <60 at BL: +0.40
• eGFR ≥60 at BL: −1.75
Mean change in sCr at Week 48,
mg/dl
• eGFR <60 at BL: +0.004
• eGFR ≥60 at BL: +0.014
Pts with serum phosphorus <2.5 mg/
dl
• BL: 2.6%
• Week 48: 4.2%

Mean urinary L-FABP level, μg/gCr
• BL: 4.32
• Week 4: 2.96; P = 0.039
No significant change in eGFR,
fractional tubular reabsorption
of phosphate or serum
phosphorus

Mean % change in sCr at Week 24
• TAF: +3.0%
• ETV: +1.7%; P = 0.278
Mean % change in eGFR at Week 24
• TAF: +1.1%
• ETV: +1.5%; P = 0.707
eGFR <50 ml/min/1.73 m2 in one pt
per group
No significant changes in serum
phosphorus or urinary β2M
levels

Renal effects
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tients switched from TDF), HBV DNA decreased, ALT significantly
decreased and eGFR stabilised after TAF switching.44 The effect on
eGFR was most pronounced in patients with stage 2 CKD. A similar result was also reported in a retrospective analysis of 121 patients switched from TDF or other NAs (prior TDF: n = 91) to TAF,

51% of whom had eGFR below 90 ml/min at baseline.52 While no
significant change in eGFR from baseline was observed in the total
population, eGFR significantly increased in the subgroup with CKD
after switch. CKD stage improvements have also been reported in
other studies.36,43,51 In the Phase 3 TDF to TAF switch study, the
proportion of patients with at least one CKD stage improvement
was significantly higher in TAF-treated patients compared with
TDF-treated patients (25% vs 8%, P < 0.0001), and the proportion
of patients with at least one CKD stage worsening was significantly
higher in TDF-treated patients compared with TAF-treated patients
(14% vs 6%, P < 0.0001).36 In a retrospective analysis of switching,
patients with reduced eGFR (<90 ml/min) at baseline had significant
decreases in eGFR while on TDF, but not after TAF switch.51 After
Week 96 of switching to TAF, approximately one-fifth of patients
with mildly decreased eGFR (60–89 ml/min) improved to normal
range, and approximately one-third of patients with moderately decreased eGFR (below 60 ml/min) improved to eGFR 60–89 ml/min.
Multivariate analysis showed that worsening eGFR was associated
with older age, male sex and poor baseline eGFR (60–89 ml/min and
below 60 ml/min vs at least 90 ml/min) at switch (P < 0.001 for all).

with switching from TDF to TAF. However, available results have
demonstrated improved or maintained virological and biochemical
responses after switching from ETV to TAF. Renal safety measures
either declined or improved slightly, or were stable. Bone safety
measures were not reported in most studies (Table 3, Figures 1 and
2).49,54-62

1.3.1 | Virological and biochemical response
Results from a retrospective study of 191 patients with CHB who
≤30 IU/L for males; ≤19 IU/L for females.

Central laboratory (≤40 U/L), AASLD 2018 (≤35 IU/L for males; ≤ 25 IU/L for females).

Data on switching from ETV to TAF are more limited compared

c

b

<50 U/L.

1.3 | Switching from ETV to TAF

a

Yan 2021

Abbreviations: AASLD, American Association for the Study of Liver Diseases; ALT, alanine aminotransferase; β2M, β2 microglobulin; BL, baseline; CKD, chronic kidney disease; CR, creatinine; eGFR,
estimated glomerular filtration rate; ETV, entecavir; FGF, fibroblast growth factor; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; L-FABP, liver-t ype fatty acid-
binding protein; NA, nucleos(t)ide analogue; NR, not reported; ns, not significant; pt, patient; sCr, serum creatinine; TAF, tenofovir alafenamide; UA/Cr, urinary albumin to creatinine; y, years.

NR
NR
Pts with normal ALT
(central)b at Week 24
• TAF: 92.6%
• ETV: 80.6%; P < 0.05
Pts with HBV DNA <30 IU/ml at
Week 12
• TAF: 41.8%
• ETV: 8.0%; P < 0.001
Pts with HBV DNA <30 IU/ml at
Week 24:
• TAF: 79.4%
• ETV: 9.1%; P < 0.001
Retrospective,
single centre

N = 499 (switched to TAF n = 104)
Mean age: 46 y (TAF), 42 y (ETV)
Male: 65% (TAF), 72% (ETV)
Mean HBV DNA level at BL, log IU/
ml: 3.2 (TAF), 3.0 (ETV)
HBeAg +ve: NR
Mean ALT level at BL, U/L: 39 (TAF),
34 (ETV)

ETV: 100%
Other: NR

Bone effects
ALT
HBV DNA
Type of study

62

Study

TA B L E 3 (Continued)

Pt population

Prior NAs

Effectiveness

Safety

Renal effects

the Canadian Hepatitis B Network who switched to TAF (126 pa-

switched to TAF after at least 2 years of ETV treatment showed
that most patients with partial virological response to ETV at
baseline achieved HBV DNA suppression at Week 48. 59 Similar
results were reported from a real-world study of 425 patients
switched from ETV to TAF. 54 The proportion of patients with
HBV DNA below 20 IU/ml significantly increased at 96 weeks
after TAF switching. In a retrospective study of 499 patients with
suboptimal response to ETV, significantly more patients switched
to TAF had HBV DNA below 30 IU/ml and normal ALT at Week
24 compared with those continuing on ETV. 62 Results from a
prospective, single-centre study of 92 patients following switch

63

Pt population

N = 93
Median age: 65 y
Male: 74%
Pts with renal impairment
Mod-sev RI:b n = 78
ESRD:b n = 15
HBV DNA <20 IU/ml for ≥6 months
HBeAg +ve: 17%
Median ALT level at BL, U/L: 17

N = 71
Mean age: 45 y
Male: 56%
Mean HBV DNA level at BL, IU/
ml: 839
HBeAg +ve: 11%
Mean ALT level at BL, U/L: 29

Prospective,
multicentre, open-
label, Week 48
analysis
GS-US-320-4 035

Retrospective, single
centre

Alghamdi
202066

N = 31
Median age: 57 y
Male: 68%
Pts with hepatic impairment CPT
class A: 61% CPT class B: 29%
CPT class C: 10%
Pts with HBV DNA <20 IU/ml at
BL: 100%
HBeAg +ve: 10%
Median ALT level at BL, U/L: 27
Prospective,
N = 31
multicentre, open- See Lim 2019 for study details
label, Week 48
analysis
GS-US-320-4 035

Prospective,
multicentre, open-
label, Week 24
analysis
GS-US-320-4 035

Type of study

NR

TDF: 68%
ETV: 45%
LAM: 45%
ADV: 32%
TBV: 6%
CLV: 3%
TDF: 62%
ETV: 46%
LAM: 49%
ADV: 49%
TBV: 6%
CLV: 2%

TDF: 68%
ETV: 45%
LAM: 45%
ADV: 32%
TBV: 6%
CLV: 3%

Prior NAs

Switching of patients from other NAs/combinations of NAs to TAF

Janssen
202065

Lim 202064

Lim 2019

Study

TA B L E 4

ALT

Mean HBV DNA level
at Month 6, IU/ml
• 17; P = 0.043

Mean ALT level at Month
6, U/L
• 27; P = 0.328

Pts with HBV DNA
Pts with normal ALT
<20 IU/ml at Week
(AASLD)a at Week 48
48
• 81%
• 100%
ALT normalisation at Week
48
• 60%
Pts with HBV DNA
Pts with normal ALT
<20 IU/ml
(AASLD)a at Week 48
• Mod-sev RI
• Mod-sev RI: 87%
BL: 99%
• ESRD: 80%
Week 48: 92%
• ESRD
BL: 93%
Week 48: 93%

Pts with normal ALT
Pts with HBV DNA
(AASLD)a at Week 24:
<20 IU/ml at Week
• 81%
24
• 100%
ALT normalisation at Week
24:
• 60%

HBV DNA

Effectiveness

Median % change in spine
BMD at Week 48
• Mod-sev RI: +1.06
• ESRD: −0.04
Median % change in hip
BMD at Week 48
• Mod-sev RI: +0.27
• ESRD: −1.74
Median % change in spine
BMD at Week 48 in
mod-sev RI group
• Prior TDF: +2.1
• Prior other NA: −0.01
Median % change in hip
BMD at Week 48 in
mod-sev RI group
• Prior TDF: +1.0
• Prior other NA: −0.9
NR

Median % change to
Week 48
• Spine BMD: +0.54
• Hip BMD: −0.19

Median % change to
Week 24
• Spine BMD: +1.53
• Hip BMD: +0.64
• CTX: −12.8
• P1NP: −11.9

Bone effects

Safety

Non-significant decline in
sCr levels at Month 6

Median change to Week 48
in mod-sev RI group
• eGFRCG: +0.8 ml/min
• Serum phosphorus:
0.0 mg/dl
• RPB/Cr ratio: −42.4%
• β2M/Cr ratio: −50.9%
• sCr, mg/dl: All: −0.05
• Prior TDF: −0.04
• Prior other NA: −0.05

Median change to Week 48
• sCr: 0.0 mg/dl
• Phosphate: −0.1 mg/dl

Median change to Week 24
• eGFRCG: + 3.0 ml/min
• sCr: 0.0 mg/dl
• Phosphate: 0.0 mg/dl
• RBP/Cr ratio: −10.9%
• β2M/Cr ratio: −21.3%

Renal effects
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N = 500
Median age: 55 y
Male: 66%
Pts with undetectable HBV DNA at
BL: 58%
HBeAg +ve: 24%
Median ALT level at BL, U/L: 29
N = 104
Median age: 64 y
Male: 41%
HBV DNA negative
HBeAg +ve: NR
Median ALT level at BL, IU/L: 31

N = 122
Median age: 61 y
Male: 66%
HBV DNA level (IU/ml) at BL:
• <20: 92.6%
• 20–2000: 7.4%
• >2000: 0%HBeAg +ve: 23%
Median ALT level at BL, U/L: 20
History of HCC: 18.0%

N = 71
Mean age: 57 y
Male: 55%
Pts with HBV DNA <20 IU/ml at
BL: 100%
HBeAg +ve: NR
Mean ALT level at BL, U/L: 24

Observational,
multicentre
TARGET-HBV cohort

Retrospective, single
centre

Retrospective,
multicentre

Prospective,
multicentre
Interim analysis

Bernstein
202167

Komorizono
202068

Ogawa
202059

Ogawa
202160

Pt population

Type of study

(Continued)

Study

TA B L E 4

Pts with undetectable
HBV DNA (prior
NA cohort)
• BL: 77.3%
• Month 12–18:
82.8%

HBV DNA
Pts with normal ALT
(central; prior NA
cohort)a
• BL: 79.8%
• Month 12–18: 85.5%

ALT
NR

Bone effects

Safety

Pts with HBV DNA
<20 IU/ml
• BL: 92.6%
• Week 48: 98.4%
HBV DNA <20 IU/ml
at Week 48 by BL
level
• 20–2000 (n = 9):
77.8%

TDF or ADV:
Pts with HBV DNA
87%
<20 IU/ml at
Other: 13%
Month 12
(not
• 100%
included in
analysis)

LAM/ADV:
36%
LAM/TDF:
32%
ETV/TDF: 30%
ETV/ADV: 3%
Median
prior NA
treatment
duration:
4.3 years

NR

NR

Pts with normal ALTc:
• BL: 63.7%
• Week 48: 69.4%;
P = 0.35

Pts with normal ALTc
• BL: 74.2%
• Month 12: 84.2%

ETV: 64%
HBV DNA negative pts No significant difference in NR
TDF: 24%
• BL: 100%
ALT levels (P = 0.449)
LAM/ADV: 8% • Week 24: 100%No
LAM/TDF: 2%
difference
ETV/ADV: 2%
according to prior
NA

Any NA: 82%
TDF: 72%

Prior NAs

Effectiveness

|
(Continues)

No significant difference in
eGFR (P = 0.124)
No significant difference
in serum phosphorus
levels (P = 0.119),
except for the TDF-TAF
group, which showed
a significant increase
(P = 0.014)
Mean change in eGFR at
Week 48, ml/min/1.73 m2
• eGFR <60 at BL: +2.68
• eGFR ≥60 at BL: −0.61;
p < 0.001
Mean change in sCr at
Week 48, mg/dl
• eGFR <60 at BL: −0.061
• eGFR ≥60 at BL: +0.008
Pts with serum
phosphorus < 2.5 mg/dl
• BL: 18.9%
• Week 48: 12.3%;
P = 0.15Urinary β2M/
Cr ratio significantly
reduced in both
groups (P < 0.001); no
significant difference
between groups
NR

Pts with CrCl >60 ml/min
(prior NA cohort)
• BL: 85.5%
• Month 12–18: 85.5%

Renal effects

LIM et al.
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Retrospective

Prospective,
multicentre, open
label
Interim results

Real world

Sripongpun
202070

Yeh 202071

Zhao 202172

Prior NAs

TDF: 73%
ADV: 64%
LAM: 58%
ETV: 36%
Long-term (>10
years) prior
treatment:
n = 19
Short-term prior
treatment:
n = 14
N = 11
TDF: 100%
Mean age: 62 y
ETV: 18%
Male: 73%
Mean prior NA
Pts with undetectable HBV DNA at
treatment
BL: 100%
duration:
HBeAg +ve: NR
4.1 years
Mean ALT level at BL, U/L: 41
Pts after liver transplant
N = 24
ETV: 58%
Median age: 53 y
TDF: 38%
Male: 29%
LAM: 4%
Median HBV DNA at BL: 64 IU/ml
HBeAg +ve: 42%
Median ALT level at BL, U/L: 24
Pts with advanced fibrosis and
partial virological response
N = 34
TDF: 38%
Mean age: 49 y
ETV: 21%
Male: 91%
HBV DNA level at BL: NR
HBeAg +ve: NR
ALT level at BL: NR
Pts with diabetes mellitus

Pt population

N = 33
Mean age: 62 y
Male: 70%
Pts with HBV DNA >20 IU/ml at
BL: 0%
HBeAg +ve: 33%
Mean ALT level at BL, U/L: 23

ALT
No significant change in
mean ALT levels in
either group

NR

Pts with undetectable
HBV DNA
• BL: 0%
• Week 24: 75%

NR

Pts with normal ALT
(central)a
• BL: 91.7%
• Week 24: 100%

Pts with unidentifiable Median change in ALT at
HBV DNA at Week
Week 48, U/L
48
• −6; P = 0.04
• 100%

Pts with HBV DNA
>20 IU/ml at
Month 6
• 0%

HBV DNA

Effectiveness

NR

NR

NR

Mean BAP levels, μg/L
• Long-term group
• BL: 21.1
• Month 6: 19.2;
p = 0.0678
• Short-term group
• BL: 17.9
• Month 6: 15.5;
p = 0.0016

Bone effects

Safety
Renal effects

16 pts had renal injury
including 9 with TDF-
related kidney injury
Urine β2M decreased upon
switching from TDF to
TAF (P = 0.005)

No significant changes in
sCr or eGFR levels from
BL to Week 24

Median change in GFR
at Week 48, ml/
min/1.73 m2
• +2.5; P = 0.2

Significant improvements
in β2M/Cr ratio in long-
term group (P = 0.0017)
and short-term group
(P = 0.0052)
Non-significant
improvements in eGFR

c

≤30 IU/L for males, ≤19 IU/L for females.

Moderate–severe RI defined as eGFRCG 15–<60 ml/min and ESRD defined as eGFRCG < 15 ml/min on chronic haemodialysis;

Central laboratory (≤40 U/L), AASLD 2018 (≤35 IU/L for males; ≤ 25 IU/L for females).

|

b

a

Abbreviations: AASLD, American Association for the Study of Liver Diseases; ADV, adefovir; ALT, alanine aminotransferase; β2M/Cr, β2 microglobulin to creatinine; BAP, bone-specific alkaline
phosphatase; BL, baseline; BMD, bone mineral density; CLV, clevudine; CPT, Child-Pugh Score; CrCl, creatinine clearance; CTX, C-t ype collagen sequence; eGFR, estimated glomerular filtration rate;
eGFRCG , estimated glomerular filtration rate Cockcroft-Gault formula; ESRD, end-stage renal disease; ETV, entecavir; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; HCC, hepatocellular carcinoma;
LAM, lamivudine; NA, nucleos(t)ide analogue; NR, not reported; P1NP, procollagen type 1 N-terminal propeptide; pt, patient; RBP/Cr, retinol binding protein to creatinine; RI, renal impairment; TAF,
tenofovir alafenamide; TBV, telbivudine; TDF, tenofovir disoproxil fumarate; sCr, serum creatinine; y, years.

Type of study

Retrospective, single
centre

Study

(Continued)

Sano 202169
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from ETV to TAF showed that two patients with HBV DNA above

35.7% had stage 2 CKD and 8.8% had stage 3–5 CKD. 54 There was

20 IU/ml at baseline achieved HBV DNA below 20 IU/ml after TAF

a significant decrease in eGFR levels after switching from ETV to

switching. 61 Multivariate analysis found that HBV genotype and

TAF, but no significant change in the distribution of CKD groups.

serum aspartate aminotransferase level at the time of switching

Multivariate analysis showed that stage 2 and stage 3–5 CKD at

were associated with superiority of TAF over ETV. Results from a

baseline were associated with lower eGFR after switching from

prospective study of 199 patients switched to TAF after at least

ETV to TAF, but most patients had stage 1 CKD throughout the

12 months of ETV showed that virological response numerically

study.

increased over 12 months. 60 A prospective study compared TAF
switching with continuing ETV in 211 ETV-t reated CHB patients
with low-level viraemia (HBV DNA 20–2000 IU/ml). 58 Significant
improvements in the proportion of patients with HBV DNA below

1.4 | Switching from other NAs or combinations of
NAs to TAF

20 IU/ml at Week 24 and ALT normalisation were reported in the
TAF group compared with the ETV group. Switching from ETV to

Studies evaluating switching from other NAs or combinations of NAs

TAF favoured HBV DNA level below 20 IU/ml at Week 24 regard-

to TAF have shown improved or maintained virological and biochem-

less of sex, age, CHB family history, HBV DNA and liver cirrhosis.

ical responses. Most study results showed that renal safety measures were stable or improved upon switching to TAF. Bone-related
safety outcomes were not reported (Table 4).59,60,63-72

1.3.2 | Renal and bone safety
Renal parameters slightly decreased, increased or were maintained in

1.4.1 | Virological and biochemical response

ETV to TAF switching studies (Table 3).49,54-59,61 Results from a retrospective study showed that patients had small numerical increases

Results from a retrospective review of 104 patients with CHB who

in serum creatinine from baseline to Week 48 after switching from

switched to TAF from various NAs showed that all patients still

ETV to TAF.59 Estimated GFR slightly increased in patients with eGFR

tested negative for HBV DNA at Week 24.68 No significant changes

below 60 ml/min; approximately 20% of these patients improved to

in ALT levels were reported. Virological response was maintained in

eGFR of at least 60 ml/min after 48 weeks of TAF. In a prospective

a prospective multicentre study of 62 patients switched to TAF after

ETV to TAF switch study, no significant changes in eGFR or inorganic

at least 12 months of any NA treatment.59 Improvements in efficacy

phosphate levels were reported.

61

In another prospective study, simi-

upon switching to TAF were also reported in several other studies

lar renal safety was observed in patients switching to TAF or continu-

(Table 4).60,66,67,69,71 A retrospective observational study evaluated

ing ETV treatment.

58

A prospective single-centre study of 48 patients

71 patients who switched to TAF after at least 6 months of treat-

treated with ETV for at least 2 years who either switched to TAF or

ment with various NAs.66 HBV DNA levels decreased significantly

56

over 6 months after TAF switching. Reasons for TAF switching in-

Results from this study showed no significant difference in markers of

cluded TDF unavailability (82%), side effects (14%), lack of efficacy,

glomerular or kidney tubule function after 48 weeks between treat-

safety concerns and physician preference (1% each). Results from

ment groups. Mean eGFR levels in the ETV group were slightly re-

the US TARGET-HBV cohort study showed that switching to TAF

duced over 48 weeks compared with stable levels in the TAF group.

was well tolerated and associated with further improvement in

continued ETV excluded patients with eGFR below 60 ml/min.

serum ALT and a decrease in HBV DNA to undetectable levels.67
Reasons for switching included perceived safety profile (35%), phy-

1.3.3 | Additional safety outcomes of interest

sician choice (23%), renal insufficiency or disease (11%) and risk of
bone disease (6%).

Results from a prospective study of CHB patients with low-level viraemia showed that 4% of TAF-treated patients experienced Grade
3 elevations in fasting LDL cholesterol, but the authors concluded

1.4.2 | Renal and bone safety

that these were isolated events in patients with a history of dyslipidaemia and/or elevated LDL cholesterol. 58 Results from a ret-

Limited renal safety data are available for studies of switching to TAF

rospective study of patients with suboptimal response to ETV did

from other NAs (Table 4).59,63,65-69,71 Results from a retrospective re-

not show any significant changes in lipids after 24 weeks of TAF.

62

view of 104 patients who switched to TAF from various NAs showed
maintenance of eGFR and serum phosphorus after switching, although a significant increase in serum phosphorus was reported in

1.3.4 | Special patient populations

those with prior TDF treatment.68 In two Phase 2 studies conducted
in virally suppressed patients with hepatic impairment and eGFR of

A retrospective real-world study of 425 patients switched from

at least 30 ml/min64 or moderate–severe renal impairment or end-

ETV to TAF included patients with CKD; 55.6% had stage 1 CKD,

stage renal disease,65 bone and renal safety parameters were stable

18
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or improved after switching to TAF from a diverse mix of NAs.64,65

Week 48, all patients had unidentifiable HBV DNA, and ALT levels

Creatinine clearance increased slightly after TAF switching in an ob-

significantly decreased.

servational study,67 while a non-significant decline in serum creatinine levels was reported in another study.66 A retrospective study
showed that patients with eGFR below 60 ml/min showed the greatest improvement in renal glomerular and proximal tubular function

2 | D I S CU S S I O N A N D C LI N I C A L
I M PLI C ATI O N S

after TAF switching.59 Estimated GFR at Week 48 after TAF switching was significantly improved in patients with CKD compared with

TAF has been available since 2016, is the most recently approved

patients without CKD.

NA and is now included, along with TDF and ETV, as a preferred
treatment option for patients with CHB in guidelines. 3-6 ,12,35 These
guidelines recommend TAF or ETV instead of TDF in patients with

1.4.3 | Special patient populations

risk of bone or renal complications, and in elderly patients. TAF
is preferred over ETV in patients with previous NA exposure be-

A Phase 2 study enrolled CHB patients with renal impairment

cause of the lower risk of drug resistance. The purpose of this nar-

who had received oral antivirals for at least 48 weeks and were

rative review was to assess the available data for switching from

virally suppressed for at least 6 months prior to TAF switching. 65

other NAs to TAF in CHB patients and the clinical implications of

Two cohorts were included: the first cohort included 78 patients

these data.

with moderate to severe renal impairment (eGFR between 15 and

Given guideline recommendations, it is not surprising that studies

60 ml/min) and the second cohort included 15 patients with end-

evaluating the efficacy and safety of TAF switching in CHB patients

stage renal disease (eGFR below 15 ml/min) on chronic haemo-

have predominantly been performed in those previously treated with

dialysis. Viral suppression was maintained in both cohorts. Renal

TDF.36-52 Phase 3 study results in patients switched to TAF or contin-

parameters were stable over 48 weeks and switching to TAF

ued on TDF showed maintenance of virological suppression at Week

caused numerical increases in BMD. Numerical increases in total,

48 in both groups.36 ALT normalisation and improvements in bone

LDL and HDL cholesterol and a small decrease in total to HDL cho-

and renal safety outcomes upon switching to TAF were also reported.

lesterol ratio were reported at Week 48. Greater increases in total,

Similar results have been reported in other studies, where virological,

LDL and HDL cholesterol were observed in patients with prior TDF

biochemical and bone and renal safety outcomes were improved or

treatment, and decreases in these parameters were observed in

maintained in patients upon switching from TDF to TAF.40-4 4,46-52

patients who received prior treatment with other NAs compared

There are several reasons why a patient with CHB may switch

with the overall population. Median body weight increased by 1 kg

NA treatment, including safety, resistance concerns and guideline

over the 48-week study.

recommendations. Most studies identified in this narrative review

A phase 2 study in 31 virally suppressed patients with hepatic

did not specify reasons for TAF switching. However, where rea-

impairment and eGFR of at least 30 ml/min evaluated switching

sons were given, these were most commonly related to safety is-

to TAF. 63,64 Hepatic impairment was defined as a Child–Turcotte–

sues.41,55,67,73 Efficacy has also been reported as a reason for TAF

Pugh (CTP) score of between 7 and 12 or a documented CTP

switching.55,73 Virological breakthrough on NA treatment may be re-

score of at least 7 in the past and any CTP score of 12 or below

lated to medication non-adherence.4,5 Results from a meta-analysis

at screening. After TAF switching, viral suppression was main-

of 30 studies of CHB patients where ETV was the most common

tained and improvements in renal and bone safety were reported.

NA used showed that NA adherence was 74.6%.74 Results from a

Estimated GFRCG levels increased, tubular markers decreased,

population-based historical cohort study of CHB patients treated

BMD increased and bone turnover markers decreased. Numerical

with ETV in Korea found that 18.6% of patients had adherence levels

increases in total, LDL and HDL cholesterol were reported at Week

below 80%.75 However, lack of adherence is not necessarily a reason

48 with greater increases observed in patients who received prior

to switch NA treatment based on the available data. Another reason

TDF treatment compared with the overall population. No differ-

for TAF switching is resistance concerns with ETV and older antiviral

ence in total to HDL cholesterol ratio was reported. Median body

agents. Data presented within this review support the use of TAF

weight increased by 2 kg over the 48-week study. No changes in

as an alternative to TDF in patients with multidrug-resistant CHB.42

CTP score were reported.

It should be noted that a recent study of two patients with viral

Preliminary results from a prospective cohort of 24 CHB pa-

breakthrough on TDF identified a quadruple mutation associated

tients with advanced fibrosis have been reported.71 Patients with

with tenofovir resistance.17 This quadruple mutation could have a

detectable HBV DNA after at least 1 year of NA treatment were

negative impact on TAF antiviral potency. However, in another study

included. After 24 weeks of TAF treatment, three-quarters of pa-

of 3886 patients enrolled in HBV clinical studies, only two patients

tients had undetectable HBV DNA. ALT normalisation rates in-

carried the quadruple resistance mutation at baseline, and both pa-

creased after TAF switching, but no significant changes in serum

tients achieved viral suppression after TDF or TAF treatment.18 No

creatinine or eGFR levels were observed. A retrospective study

evidence of resistance to TDF or TAF and no selection of those mu-

evaluated TAF switching in 11 patients after liver transplant.70 At

tations after starting TDF or TAF was observed.
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Treatment guidelines provide recommendations on which pa-

TDF has a favourable long-term safety profile, but renal tu-

3,5,6,12,13

bular dysfunction and BMD loss have been reported in some pa-

One study switched patients to TAF according to EASL criteria.3,48

tients.19-27 In Phase 3 studies of CHB patients, TAF demonstrated

Virological and biochemical parameters remained stable after TAF

improved renal and bone safety compared with TDF.19 Several stud-

switching, and improvements in renal function were reported.48

ies showed that switching from TDF to TAF improved both renal and

Results from the studies summarised herein support the concept

bone safety.36-41,43,44,46-52 Bone safety was not reported in most

of switching to TAF based on guideline criteria. However, there ap-

studies of TAF switching from ETV or other NAs. With respect to

pears to be a reluctance to switch patients despite evidence-based

renal safety, switching from ETV or other NAs to TAF had no clear

guidelines. A cross-sectional study performed in two European hos-

benefit.49,54-59,61,63-72

tients should be considered for TAF switching (Table 1).

pitals estimated that two-thirds of patients who could benefit from

Significant lipid changes were not observed in patients switch-

switching to ETV or TAF based on EASL guideline criteria remained

ing from ETV to TAF,62 but patients who switched from TDF to TAF

on TDF.76 Several studies have evaluated TAF switching in special

had greater increases in total, LDL and HDL cholesterol compared

patient populations, such as those with CKD, hepatic impairment,

with those who continued TDF treatment.39,42 This could be due

liver fibrosis or transplantation.

44,51,52,54,63-65,70,71

Pregnant women

to high plasma tenofovir levels in TDF-treated patients, which has

and children are also important patient populations to consider with

been linked to lipid reductions in patients on TDF.19,81 Therefore, it

respect to NA treatment. While there are no TAF switching stud-

is possible that changes in lipid levels after TAF switching represent

ies in pregnant women, studies of TAF during pregnancy have been

“returning to normal”. It should be noted that the total to HDL cho-

conducted. Three studies that evaluated TAF treatment in pregnant

lesterol ratio did not increase after switching from TDF to TAF,39,42

women reported that TAF could effectively reduce maternal HBV

suggesting no increased risk of CVD.82 The clinical impact of lipid

77-79

transmission with no observed safety concerns,

suggesting that

changes upon switching from TDF to TAF is uncertain, but never-

TAF switching may be appropriate in these patients, although it is

theless, a patient’s individual CVD risk should be considered when

not indicated for such use. ETV and TDF have been studied in chil-

switching to TAF. Some studies reported body weight increase in

dren with CHB,3-5 while TAF is currently under investigation in this

patients who switched from TDF to TAF.39,42,47,64,65 The reported

setting. Findings from an ongoing study of TAF efficacy and safety

weight gains were in line with the reported average of 1 kg per

in children and adolescents with CHB (NCT02932150) will inform

year,83,84 although among patients with hepatic impairment, the me-

future clinical guidance in this population.

dian weight (Q1, Q3) at baseline was 71 kg (59, 87) and 73 kg (61,

To date, few studies have evaluated switching from ETV, or

89) in TDF- and TAF-treated patients, respectively.64 It is uncertain

NAs other than TDF, to TAF, but this evidence base is growing.

whether TAF affects body weight, particularly given the lipid- and

Improvements in virological outcomes upon switching from ETV to

weight-suppressive effects of TDF. The observed rise in lipids and

TAF have been shown in several studies.

54,55,58-62

Low-level viraemia

during ETV monotherapy is associated with a high risk of HCC and

weight following switch from TDF to TAF and not ETV to TAF might
be reflective of this effect.

disease progression,16,80 and the American Association for the Study

Although maintenance or improvements in virological, biochem-

of Liver Diseases guidelines recommend that patients with low-level

ical and safety outcomes upon TAF switching were observed, long-

viraemia on ETV switch to another antiviral monotherapy with a high

term studies are required to determine whether these translate to

barrier to resistance or add a second antiviral drug that lacks cross

long-term benefits. High viral suppression rates are associated with

resistance.5 Current data suggest that switching these patients to

improved long-term outcomes in CHB patients, and normal ALT lev-

TAF may help avoid poor long-term outcomes. Improvements or

els are associated with lower HCC incidence.85-92 Long-term out-

maintenance in virological outcomes upon switching from other NAs

comes of patients may improve upon TAF switching, but further

or combinations of NAs to TAF have been reported.59,60,63-65,67-71

investigation is warranted. The CHB patient population is ageing,

TDF and/or ETV were the most commonly reported prior NAs, but

with an increasing incidence of comorbidities.7-11 Analysis of TAF

several studies included a high proportion of patients treated with

efficacy and safety in geriatric (aged 65 years and above) vs non-

other prior NAs.

59,60,63-65,69

No differences in efficacy or safety of

geriatric patients enrolled in TAF clinical studies showed no clinically

TAF switching according to prior NA were reported in most stud-

significant differences.34 Consequently, it is imperative for physi-

ies. However, it is necessary to acknowledge that ‘other NA’ pop-

cians to choose a NA treatment that will continue to suppress viral

ulations represent a diverse group. Changes in lipids and renal and

load, not cause resistance and which has a favourable bone and renal

bone safety in patients with prior TDF were reported in some stud-

safety profile. Emerging data support TAF as a valuable treatment

ies.63-65,68,72 One study included TDF-treated patients with resis-

option in this arena. Results from studies modelling the potential

tance to adefovir and/or ETV who continued on TDF or switched

health consequences of NA treatment projected fewer liver, renal

to TAF. Virological outcomes were comparable between the two

and bone complications in patients treated with TAF compared with

treatment groups, but improvements in biochemical, bone and renal

TDF or ETV over 10 years.93-95 The renal and bone benefits associ-

outcomes were reported in the TAF group compared with the TDF

ated with TAF treatment have the potential to address comorbidities

group. These results suggest that TAF switching may be appropriate

associated with an ageing CHB population. However, a discussion of

in patients with multidrug-resistant CHB.42

the economic factors surrounding TAF is beyond the scope of this

20
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article. Additional long-term real-world data on TAF effectiveness

Author contributions: All authors contributed to review of the

and safety will provide further evidence among switch and naïve pa-

published data, drafting of the manuscript and critical revision of the

tients, as well as in the setting of transplantation and prophylaxis for

manuscript. All authors approved the final version of the article.

HBV reactivation.
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